Eva Havrdová

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

Chris H. Polman, Stephen C. Reingold, Brenda Banwell et al. · Annals of Neurology · 2011 · 9.8K citations · Full text

Medicine, Neurology, Neuroscience +10

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

Chris H. Polman, Paul O’Connor, Eva Havrdová et al. · New England Journal of Medicine · 2006 · 3.3K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

Robert J. Fox, David H. Miller, J. Theodore Phillips et al. · New England Journal of Medicine · 2012 · 1.3K citations · Full text

Medicine, Neurology, Pharmacology +6

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Jeffrey Cohen, Alasdair Coles, Douglas L. Arnold et al. · The Lancet · 2012 · 1.2K citations

Life Sciences, Immunology, Neurology +11

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Alasdair Coles, Cary Twyman, Douglas L. Arnold et al. · The Lancet · 2012 · 1.2K citations · Full text

Life Sciences, Immunology, Neurology +11